Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

NCT02435680 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

Interventions

DRUG: MCS110
DRUG: carboplatin
DRUG: gemcitabine

Sponsor

Novartis Pharmaceuticals